Locus Cell Co (6891.TWO) Akcie Kurz

Locus Cell Co., Ltd. principally engages in the entrusted development and manufacturing of cell therapy-related products. The company is headquartered in Taipei, New Taipei and currently employs 32 full-time employees. The company went IPO on 2022-04-28. The firm is currently expected to provide cell therapy contract manufacturing organization (CDMO) production and development services using a pilot Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) good manufacturing practices (GMP) facility, with related technologies for cell therapy products (expected to include tissue engineering related products, CAR-T, iPSCs, MSC and other cell therapy applications), process development and process scale-up, analytical method development and validation, clinical GMP manufacturing process for clinical trials, and stability testing.